98%
921
2 minutes
20
Purpose: The objective of this consensus is to provide otolaryngologists with appropriate strategies in the management of external auditory canal (EAC) carcinoma.
Methods: In the absence of randomized controlled trials, the consensus is based on expert opinions utilizing the Rand/UCLA appropriateness method [Fitch and Aguilar in The RAND/UCLA appropriateness method user's manual, RAND Corporation, Santa Monica, CA, 2001], drawing from existing literature and clinical experience.
Results: The management recommendations are structured around 12 key areas, including: definition and pathology, pathogenesis, clinical manifestations, work-up, tumor staging system, surgical management of primary tumor, surgical management of the parotid gland and the temporomandibular joint, lymph node metastasis, radiotherapy, chemotherapy, reconstruction, and follow-up.
Conclusion: Management strategies for EAC carcinoma rely on tumor extension and histopathological features. Surgical removal with free surgical margins or combination with radiotherapy, chemotherapy are most often the best options. Given the rarity of the disease, prospective, randomized, multi-institutional clinical trials should be designed to enable reliable comparisons of the outcomes of EAC carcinoma treatments, thereby providing evidence-based clinical data to establish widely accepted guidelines. It emphasizes the need for a multidisciplinary team to be involved in the management of EAC carcinoma, and regular follow-up should be implemented postoperatively.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00405-024-09033-w | DOI Listing |
Front Oncol
August 2025
Department of Otolaryngology, The Jikei University School of Medicine, Tokyo, Japan.
Introduction: Carcinoma of the external auditory canal (EAC) is rare, and squamous cell carcinoma (SCC) is the most common histological type. There are few reports on the treatment outcomes for a large number of cases at a single institution, and a standard treatment has not been established.
Methods: Treatment details and prognoses were retrospectively examined for patients who underwent primary treatment for SCC of the EAC at The Jikei University between April 2015 and May 2023.
Pharmaceuticals (Basel)
August 2025
Department of Pharmacy, Inje University, Gimhae 50843, Gyeongnam, Republic of Korea.
Esophageal cancer (EC), including esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), remains a lethal malignancy with limited molecularly tailored treatment options. Due to substantial histologic and transcriptomic differences between subtypes, therapeutic responses often vary, underscoring the need for subtype-stratified analysis and precision drug discovery. We integrated transcriptomic data from GEO and TCGA to identify differentially expressed genes (DEGs) specific to EAC, ESCC, and their shared profiles.
View Article and Find Full Text PDFJ Genet Eng Biotechnol
September 2025
Department of Pharmacy, University of Rajshahi, Rajshahi 6205, Bangladesh. Electronic address:
Lagerstroemia speciosa is traditionally used for treating diabetes and inflammation; however, its anticancer potential remains unexplored. This study assesses the antioxidant and anticancer activities of L. speciosa bark extract, with a focus on Ehrlich Ascites Carcinoma (EAC) cells in mice.
View Article and Find Full Text PDFGut Microbes
December 2025
Division of Digestive & Liver Diseases, Columbia University Irving Medical Center, New York, NY, USA.
Bile acids are a major component of gastro-esophageal refluxate, thought to contribute to the development of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). As the microbiome shifts with EAC progression and bile acids influence bacterial composition, we examined these connections in a multi-center, cross-sectional study. We analyzed biospecimens from patients undergoing endoscopy using LC-MS to quantify bile acids in gastric aspirates, 16S rRNA sequencing for tissue microbiome profiling, and RNA sequencing on BE or cardia tissue.
View Article and Find Full Text PDFCancer Treat Res Commun
August 2025
Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, India.
Unlabelled: External Auditory Canal (EAC) Squamous cell cancers are rare head and neck malignancies accounting for 0.2% of cancers of this region which has limited literature to guide management.We report a retrospective study patients with SCC of EAC treated at a Tertiary Cancer Centre in India.
View Article and Find Full Text PDF